← Back to Screener
Impact BioMedical, Inc. (IBO)
Price$0.66
Favorite Metrics
Price vs S&P 500 (26W)5.49%
Price vs S&P 500 (4W)42.66%
Market Capitalization$70.71M
All Metrics
Book Value / Share (Quarterly)$0.32
Cash Flow / Share (Quarterly)$-0.32
Price vs S&P 500 (YTD)31.20%
EPS (TTM)$-3.58
10-Day Avg Trading Volume0.15M
EPS Excl Extra (TTM)$-3.58
EPS (Annual)$-2.30
ROI (Annual)-188.08%
Cash / Share (Quarterly)$0.05
ROA (Last FY)-121.77%
EBITD / Share (TTM)$-1.05
Cash Flow / Share (Annual)$-0.34
P/B Ratio18.40x
P/B Ratio (Quarterly)2.74x
Net Income / Employee (Annual)$-12
Net Interest Coverage (TTM)-9.23x
ROA (TTM)-145.05%
EPS Incl Extra (Annual)$-2.30
Current Ratio (Annual)0.25x
Quick Ratio (Quarterly)0.04x
3-Month Avg Trading Volume3.06M
52-Week Price Return40.72%
Tangible BV / Share (Quarterly)$1.15
P/S Ratio (Annual)1414.27x
Asset Turnover (Annual)0.00x
52-Week High$1.95
EPS Excl Extra (Annual)$-2.30
26-Week Price Return9.48%
Quick Ratio (Annual)0.22x
13-Week Price Return39.25%
Total Debt / Equity (Annual)2.08x
Current Ratio (Quarterly)0.06x
Enterprise Value$92.442
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-15752.00%
Cash / Share (Annual)$0.17
3-Month Return Std Dev190.94%
Net Income / Employee (TTM)$-19
ROE (Last FY)-580.14%
Net Interest Coverage (Annual)-1.98x
EPS Basic Excl Extra (Annual)$-2.30
Total Debt / Equity (Quarterly)2.38x
EPS Incl Extra (TTM)$-3.58
ROI (TTM)-97.82%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)10.89%
Year-to-Date Return33.84%
5-Day Price Return-4.80%
EPS Normalized (Annual)$-2.30
Net Profit Margin (Annual)-14102.00%
Month-to-Date Return12.65%
EBITD / Share (Annual)$-2.57
Operating Margin (Annual)-15008.00%
LT Debt / Equity (Quarterly)0.25x
EPS Basic Excl Extra (TTM)$-3.58
P/TBV (Quarterly)1.73x
P/B Ratio (Annual)3.92x
Book Value / Share (Annual)$0.37
Price vs S&P 500 (13W)38.56%
Beta2.71x
ROE (TTM)-159.29%
52-Week Low$0.36
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IBOImpact BioMedical, Inc. | — | — | — | — | $0.66 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Impact BioMedical Inc develops therapeutics and preventative solutions targeting neurological, oncological, and immune-related diseases. The company also advances open-air defense technologies designed to reduce transmission of airborne infectious diseases, including tuberculosis and influenza. Its proprietary platforms include Linebacker, Laetose, 3F, and Equivir.